Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Ariana Resources (AAU) by Hot Stock Rockets in ShareProphets
- Avoid Ten Lifestyle Group (TENG) by Steve Moore in ShareProphets
- Avoid Biome Technologies (BIOM) by Steve Moore in ShareProphets
- Buy Aviva (AV.) by Harvey Jones in The Motley Fool
- Buy CMC Markets (CMCX) by Harvey Jones in The Motley Fool
- Buy ITV (ITV) by Simon Watkins in The Motley Fool
- Buy Legal & General Group (LGEN) by Simon Watkins in The Motley Fool
- Hold Vodafone Group (VOD) by DZ Bank
- Buy Premier Foods (PFD) by Jefferies
- Buy Intermediate Capital Group (ICG) by Deutsche Bank
- Overweight WH Smith (SMWH) by JP Morgan
- Outperform TT Electronics (TTG) by RBC Capital
- Buy International Consolidated Airlines Group SA (CDI) (IAG) by Goldman Sachs
- Neutral Dr. Martens (DOCS) by Goldman Sachs
- Buy Intermediate Capital Group (ICG) by Goldman Sachs
- Neutral Vistry Group (VTY) by JP Morgan
- Buy Babcock International Group (BAB) by Jefferies
- Buy Convatec Group (CTEC) by Jefferies
- Buy Altona Rare Earths (REE) by Hot Stock Rockets in ShareProphets
- Avoid Marks Electrical Group (MRK) by Steve Moore in ShareProphets
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 59 open tips for Shield Therapeutics (STX)
| Latest Bid : 2.60p | Latest Ask : 2.80p |
| High Today : 2.70p | Low Today : 2.60p |
| This Years High : 7.65p | This Years Low : 1.23p |
| Volume : 600,983 | MKT Cap : £21.9M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | 3.45% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | -66.01% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | -63.38% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-30 08:40:00 30/06/2022 | 65.00% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-12 17:55:00 12/06/2022 | 80.49% |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 2.60p | Latest Ask : 2.80p |
| High Today : 2.70p | Low Today : 2.60p |
| This Years High : 7.65p | This Years Low : 1.23p |
| Volume : 600,983 | MKT Cap : £21.9M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2024-02-21 12:20:00 21/02/2024 | 3.45% |
| Buy | William Kay | Premium Only | 2023-09-29 00:05:00 29/09/2023 | -66.01% |
| Buy | Peel Hunt | Premium Only | 2023-02-09 09:31:00 09/02/2023 | -63.38% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-30 08:40:00 30/06/2022 | 65.00% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-12 17:55:00 12/06/2022 | 80.49% |